TPST Tempest Therapeutics, Inc.

CIK 0001544227 50 ready 8-Ks latest August 24, 2026, 4:43 PM ET RSS · JSON

Activity: ELEVATED 4 filings / 30d vs 2 baseline Risk accumulating: repeated leadership change (12)

Ready 8-Ks 50

Latest filing August 24, 2026, 4:43 PM ET

Top materiality 0.95

Event mix other_material ×23 · earnings ×13 · leadership ×6

Sentiment 14 pos · 7 neg · 29 neu

Latest earnings reported 2025-Q3

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for TPST

Highest-materiality recent filing

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

February 6, 2026, 6:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 3.02 item 5.01 item 5.02 item 9.01 ◈ Equity Issuances ×2◈ M&A Transactions

Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.

Read filing →

August 24, 2026, 4:43 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change ×2

Tempest CFO Justin Trojanowski resigns Sept 1; Nicholas Rossettos appointed

Justin Trojanowski resigns as Principal Financial/Accounting Officer effective Sept 1, 2026.
August 18, 2026, 4:27 PM ET other material materiality 0.50 neutral item 5.07 item 8.01

Tempest Therapeutics adjourns special meeting again; needs 75% vote for governance change

Special meeting reconvened Aug 17, 2026, adjourned again due to insufficient votes for proposal.
August 13, 2026, 4:36 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Tempest Q2 net loss $5.2M; TPST-4003 collaboration with Senlang, first dosing Q4 2026

Q2 net loss $5.2M ($0.34/share) vs $7.9M ($2.07) year ago; cash $0.8M at June 30.
August 13, 2026, 4:31 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 9.01

Tempest Therapeutics enters $50M equity purchase agreement with Lincoln Park Capital

Up to $50M common stock purchase commitment; initial $25M available, auto-increases to $50M.
July 28, 2026, 4:50 PM ET other material materiality 0.50 neutral item 5.07 item 8.01

Tempest Therapeutics adjourns special meeting due to insufficient votes for governance amendment

Special meeting on July 27, 2026 adjourned; proposal to replace supermajority voting and allow written consent lacked sufficient votes.
July 22, 2026, 4:05 PM ET other material materiality 0.60 neutral item 1.01 item 7.01 item 9.01

Tempest partners with Senlang to develop TPST-4003 in vivo CAR-T; IIT in China expected Q4 2026

Collaboration with Hebei Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T candidate.
June 22, 2026, 8:22 PM ET other material materiality 0.15 neutral item 5.07

Tempest Therapeutics shareholders approve stock issuance for warrant exercises

Proposal 1 passed: 9,090,763 votes for issuance of up to 925,927 shares from Series A and B warrants (March 2026 private placement).
June 4, 2026, 5:00 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×4

Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors

CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.
June 1, 2026, 7:13 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances◈ Material Agreements

Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73

Holder exercises 1,172,414 existing warrants at reduced $1.73/share for ~$2M cash gross proceeds.
May 29, 2026, 5:01 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Tempest Therapeutics director Simantov resigns from Board effective May 23, 2026

Ms. Simantov resigned from the Board; no disagreement with company operations or policies.
May 22, 2026, 5:28 PM ET regulatory materiality 0.90 negative item 3.01 item 5.02 ◈ Listing & Compliance Notices ×2◈ executive_change ×2

Tempest Therapeutics warned by Nasdaq for low equity and board independence; two directors resign

Stockholders' equity of $822k vs Nasdaq's $2.5M minimum; 45 days to submit compliance plan by July 6, 2026.
May 22, 2026, 5:05 PM ET leadership materiality 0.40 negative item 5.02 ◈ executive_change ×3

Three directors resign from Tempest Therapeutics board effective May 22, 2026

Stephen Brady, Michael Raab, and Christine Pellizzari resigned from the Tempest board on May 22, 2026.
May 14, 2026, 4:28 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tempest Therapeutics reports Q1 2026 net loss of $27.7M, highlights 100% CR rate in TPST-2003 trials

Ended Q1 with $1.8M cash vs $7.7M at year-end 2025; net loss $27.7M ($2.53/share) vs $10.9M ($3.16) year ago.
May 6, 2026, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Tempest reports 100% CR rate in 15 CAR-T-naïve patients across two Phase 1 trials of TPST-2003

100% complete response rate (CR) among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 in two Phase 1 trials.
March 30, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition

Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
March 23, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances ×3◈ Material Agreements ×2

Tempest Therapeutics raises ~$2M in private placement of stock and warrants

Raised ~$2M gross from private placement of 462,964 shares + pre-funded warrants at $2.16 per unit.
February 25, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026

100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
February 11, 2026, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Tempest Therapeutics files updated corporate presentation; no specific new data disclosed in filing.

Company posted February 2026 investor presentation on its website.
February 6, 2026, 6:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 3.02 item 5.01 item 5.02 item 9.01 ◈ Equity Issuances ×2◈ M&A Transactions

Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
January 28, 2026, 6:59 PM ET other material materiality 0.50 neutral item 3.03 item 5.02 item 5.07

Tempest shareholders approve share issuance for asset purchase and extend rights plan

Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.
January 9, 2026, 6:59 PM ET other material materiality 0.35 neutral item 3.01 ◈ Listing & Compliance Notices

Tempest Therapeutics gets Nasdaq notice for missing annual meeting; meeting set for Jan 27, 2026

Received Nasdaq deficiency letter on Jan 8, 2026 for failing to hold annual meeting within 12 months of fiscal year end Dec 31, 2024.
November 26, 2025, 6:59 PM ET other material materiality 0.70 neutral item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×2

Tempest raises $4.25M upfront in registered direct offering; warrants add up to $4.1M

1,172,414 shares (or equivalents) sold at $3.625/share in registered direct offering for ~$4.25M gross.
November 19, 2025, 6:59 PM ET M&A materiality 0.85 neutral item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Tempest Therapeutics to acquire four CAR T assets in all-stock deal; CEO change, warrants issued

Acquires ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies for 8,268,495 shares of TPST common stock.
November 5, 2025, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process

Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
August 11, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Tempest Therapeutics reports Q2 2025 net loss $7.9M; cash $14.3M; pivotal HCC trial cleared in China

Cash and equivalents at June 30, 2025: $14.3M, down from $30.3M at Dec 31, 2024.
June 12, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 7.01 item 8.01 item 9.01

Tempest Therapeutics raises ~$4.6M gross in registered direct offering of stock and prefunded warrants

Issued 405,000 shares at $6.25 each and prefunded warrants for 334,000 shares at $6.249 each.
June 11, 2025, 7:59 PM ET other material materiality 0.20 neutral item 8.01

Tempest Therapeutics suspends ATM prospectus; Sales Agreement remains in effect

Delivered notice to Jefferies to terminate ATM prospectus dated Feb 6, 2025.
June 6, 2025, 7:59 PM ET leadership materiality 0.75 negative item 5.02

Tempest Therapeutics transitions CEO, CMO, and CFO to consultants with equity acceleration

CEO Stephen Brady, CMO Samuel Whiting, CFO Nicholas Maestas transitioned to consulting agreements effective June 5, 2025.
May 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives

Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
April 28, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

Tempest Therapeutics regains Nasdaq minimum bid price compliance

Received Nasdaq notice on April 24, 2025 confirming compliance with Listing Rule 5550(a)(2).
April 18, 2025, 7:59 PM ET other material materiality 0.80 negative item 2.05 ◈ Restructurings & Charges

Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review

Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.
April 9, 2025, 7:59 PM ET other material materiality 0.80 neutral item 1.02 item 7.01 item 9.01

Tempest explores strategic alternatives for pipeline; repays $3.5M loan with $0.6M exit fee

Repaid $3.5M loan in full to Oxford Finance on April 8, 2025; included $0.6M exit fee; agreement terminated.
April 7, 2025, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 9.01

Tempest Therapeutics announces 1-for-13 reverse stock split effective April 8, 2025

Reverse stock split at 1:13 ratio, effective 5:00 p.m. ET on April 8, 2025.
March 27, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations

Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.
December 31, 2024, 6:59 PM ET regulatory materiality 0.55 negative item 3.01 ◈ Listing & Compliance Notices

Tempest Therapeutics receives Nasdaq bid price deficiency notice; stock below $1.00

Received Nasdaq deficiency letter on Dec 27, 2024 for bid price below $1.00 for 30 consecutive business days.
December 6, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.03 item 5.07 item 9.01

Tempest Therapeutics stockholders approve reverse stock split proposal at ratios up to 1-for-15

Stockholders approved reverse stock split proposal at special meeting on December 3, 2024.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Tempest reports Q3 net loss $10.6M; gets FDA go-ahead for amezalpat Phase 3 in first-line HCC

Net loss of $10.6M ($0.41/sh) in Q3 2024 vs $6.8M ($0.48) in Q3 2023; cash $22.1M, then raised $19.9M net via ATM.
October 10, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 3.03 item 8.01 item 9.01

Tempest inks Roche atezolizumab supply deal for Phase 3 liver cancer trial; extends rights plan

Master clinical supply agreement with Roche for free atezolizumab in planned Phase 3 trial of amezalpat (TPST-1120) in first-line unresectable/metastatic HCC.
August 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study

Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.
June 20, 2024, 7:59 PM ET other material materiality 0.90 positive item 1.01 item 8.01 item 9.01

Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility

Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.
June 14, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Tempest Therapeutics announces 2024 annual meeting voting results

Stockholders elected Stephen Brady, Michael Raab, and Ronit Simantov as Class III directors for three-year terms.
May 9, 2024, 7:59 PM ET earnings materiality 0.55 positive item 2.02 item 9.01 ◈ Earnings Releases

Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3

Cash $32.3M at March 31, 2024; expects runway into Q2 2025.
March 19, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Tempest reports FY2023 net loss $29.5M; positive Phase 1b/2 HCC data for TPST-1120

Net loss $29.5M ($1.91/sh) vs $35.7M in 2022; cash $39.2M, runway into Q2 2025.
November 8, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Tempest Q3 net loss $6.8M; TPST-1120 shows superiority in liver cancer; cash runway into 2025

Net loss $6.8M ($0.48/share) vs $8.9M ($0.66) in Q3 2022; R&D expense fell to $4.2M from $6.0M.
October 30, 2023, 7:59 PM ET regulatory materiality 0.50 positive item 8.01

Tempest regains Nasdaq minimum bid price compliance

Received formal Nasdaq notification on Oct 26, 2023, confirming compliance with Listing Rule 5450(a)(1).
October 11, 2023, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 3.03 item 5.03 item 8.01 item 9.01 ◈ Material Agreements

Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill

Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.
September 8, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Tempest Therapeutics receives Nasdaq bid price deficiency notice, 180 days to comply

Nasdaq notified TPST on Sept 6, 2023 that bid price closed below $1.00 for 30 consecutive days.
September 7, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change ×2

Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role

Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.
August 10, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Tempest Q2 2023 net loss $7.6M; TPST-1120 HCC data shows 74% ORR improvement over control

Cash $17.6M at June 30, 2023, down from $31.2M at Dec 31, 2022.
June 16, 2023, 7:59 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×4

Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting

Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.